These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3006090)

  • 1. Hallucinogenic drug research--if so, so what? Symposium summary and commentary.
    Freedman DX
    Pharmacol Biochem Behav; 1986 Feb; 24(2):407-15. PubMed ID: 3006090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions.
    White FJ
    Pharmacol Biochem Behav; 1986 Feb; 24(2):365-79. PubMed ID: 3952127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures.
    Appel JB; White FJ; Holohean AM
    Neurosci Biobehav Rev; 1982; 6(4):529-36. PubMed ID: 7177512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.
    Winter JC
    Psychopharmacology (Berl); 2009 Apr; 203(2):251-63. PubMed ID: 18979087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
    Hungen KV; Roberts S; Hill DF
    Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nature of opioid and LSD receptors: structural activity relationship implications.
    Martin WR
    NIDA Res Monogr; 1978; (22):60-9. PubMed ID: 30913
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.
    Killinger BA; Peet MM; Baker LE
    Pharmacol Biochem Behav; 2010 Sep; 96(3):260-5. PubMed ID: 20493209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
    Marona-Lewicka D; Nichols DE
    Pharmacol Biochem Behav; 2007 Oct; 87(4):453-61. PubMed ID: 17618679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nerve terminal effects of indoleamine psychotomimetics on 5-hydroxytryptamine.
    Halaris AE
    Neurosci Biobehav Rev; 1982; 6(4):483-7. PubMed ID: 6294571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity-relationships of certain hallucinogenic substances based on brain levels.
    Vogel WH; Evans BD
    Life Sci; 1977 May; 20(10):1629-35. PubMed ID: 69244
    [No Abstract]   [Full Text] [Related]  

  • 11. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.
    Sloviter RS; Drust EG; Damiano BP; Connor JD
    J Pharmacol Exp Ther; 1980 Aug; 214(2):231-8. PubMed ID: 6104720
    [No Abstract]   [Full Text] [Related]  

  • 12. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.
    Benneyworth MA; Smith RL; Barrett RJ; Sanders-Bush E
    Psychopharmacology (Berl); 2005 Jun; 179(4):854-62. PubMed ID: 15645221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of CNS tryptaminergic processes and the action of LSD-like hallucinogens.
    Martin WR; Sloan JW
    Pharmacol Biochem Behav; 1986 Feb; 24(2):393-9. PubMed ID: 3006088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats.
    Trulson ME; Heym J; Jacobs BL
    Brain Res; 1981 Jun; 215(1-2):275-93. PubMed ID: 6114779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives.
    Huang X; Marona-Lewicka D; Pfaff RC; Nichols DE
    Pharmacol Biochem Behav; 1994 Mar; 47(3):667-73. PubMed ID: 8208787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships in potentially hallucinogenic N,N-dialkyltryptamines substituted in the benzene moiety.
    Kline TB; Benington F; Morin RD; Beaton JM
    J Med Chem; 1982 Aug; 25(8):908-13. PubMed ID: 7120280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature of the binding between LSD and a 5-HT receptor: a possible explanation for hallucinogenic activity.
    Berridge MJ; Prince WT
    Br J Pharmacol; 1974 Jun; 51(2):269-78. PubMed ID: 4375525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral effects of intracerebroventricular administration of LSD, DOM, mescaline or lisuride.
    Mokler DJ; Rech RH
    Pharmacol Biochem Behav; 1984 Aug; 21(2):281-7. PubMed ID: 6483939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
    Rickli A; Moning OD; Hoener MC; Liechti ME
    Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-hallucinogen interactions.
    Domino EF
    Pharmacol Biochem Behav; 1986 Feb; 24(2):401-5. PubMed ID: 3006089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.